This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kraiczy, P.
Right arrow Articles by Hunfeld, K.-P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kraiczy, P.
Right arrow Articles by Hunfeld, K.-P.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2001, p. 2486-2494, Vol. 45, No. 9
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.9.2486-2494.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

In Vitro Activities of Fluoroquinolones against the Spirochete Borrelia burgdorferi

Peter Kraiczy,1 Judith Weigand,1 Thomas A. Wichelhaus,1 Peter Heisig,2 Herbert Backes,3 Volker Schäfer,1 Georg Acker,4 Volker Brade,1 and Klaus-Peter Hunfeld1,*

Institute of Medical Microbiology, University Hospital of Frankfurt, D-60596 Frankfurt/Main,1 Pharmaceutical Microbiology, University of Bonn, D-53115 Bonn,2 Merlin GmbH, D-53332 Bornheim-Hersel,3 and Department of Biological Electron Microscopy, University of Bayreuth, D-95440 Bayreuth,4 Germany

Received 8 March 2001/Returned for modification 25 May 2001/Accepted 14 June 2001

Little is known to date about the in vitro activity of fluoroquinolones against Borrelia species. Our study aimed at determining the in vitro activities of 15 quinolones against nine isolates of the Borrelia burgdorferi sensu lato complex in addition to one Borrelia valaisiana and one Borrelia bissettii tick isolate. For the determination of MICs, a standardized colorimetric microdilution method was applied. Determination of minimal borreliacidal concentrations providing 100% killing of the final inoculum (MBCs) after 72 h and time-kill experiments were performed by conventional culture in Barbour-Stoenner-Kelly medium in combination with dark-field microscopy. The rank order of potency on a microgram-per-milliliter basis for the substances with in vitro activity against B. burgdorferi was gemifloxacin (MIC at which 90% of the isolates tested are inhibited [MIC90], 0.12 µg/ml) > sitafloxacin (MIC90, 0.5 µg/ml), grepafloxacin (MIC90, 0.5 µg/ml) > gatifloxacin (MIC90, 1 µg/ml), sparfloxacin (MIC90, 1 µg/ml), trovafloxacin (MIC90, 1 µg/ml) > moxifloxacin (MIC90, 2 µg/ml), ciprofloxacin (MIC90, 2 µg/ml) > levofloxacin (MIC90, 4 µg/ml) > ofloxacin (MIC90, 8 µg/ml), norfloxacin (MIC90, 8 µg/ml) > fleroxacin (MIC90, >16 µg/ml), and pefloxacin (MIC90, 32 µg/ml) > nalidixic acid (MIC90, 256 µg/ml). After 72 h of exposure, gemifloxacin was borreliacidal (100% killing) against the isolates investigated at a median MBC of 4 µg/ml. In the other compounds tested, median MBCs were higher (>= 8 µg/ml). Results of electron microscopy and time-kill studies clearly support an in vitro activity of some fluoroquinolones against borreliae. Our study demonstrates for the first time the enhanced in vitro effectiveness of some of the recently introduced 4-quinolones against B. burgdorferi.

* Corresponding author. Mailing address: Institute of Medical Microbiology, University Hospital of Frankfurt, Paul-Ehrlich-Str. 40, D-60596 Frankfurt/Main, Germany. Phone: 49-69-6301-6441. Fax: 49-69-6301-5767. E-mail: K.Hunfeld{at}em.uni-frankfurt.de.

Antimicrobial Agents and Chemotherapy, September 2001, p. 2486-2494, Vol. 45, No. 9
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.9.2486-2494.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Brorson, O., Brorson, S.-H., Scythes, J., MacAllister, J., Wier, A., Margulis, L. (2009). Destruction of spirochete Borrelia burgdorferi round-body propagules (RBs) by the antibiotic Tigecycline. Proc. Natl. Acad. Sci. USA 106: 18656-18661 [Abstract] [Full Text]  
  • Morgenstern, K., Baljer, G., Norris, D. E., Kraiczy, P., Hanssen-Hubner, C., Hunfeld, K.-P. (2009). In Vitro Susceptibility of Borrelia spielmanii to Antimicrobial Agents Commonly Used for Treatment of Lyme Disease. Antimicrob. Agents Chemother. 53: 1281-1284 [Abstract] [Full Text]  
  • Galbraith, K. M., Ng, A. C., Eggers, B. J., Kuchel, C. R., Eggers, C. H., Samuels, D. S. (2005). parC Mutations in Fluoroquinolone-Resistant Borrelia burgdorferi. Antimicrob. Agents Chemother. 49: 4354-4357 [Abstract] [Full Text]  
  • Hunfeld, K.-P., Ruzic-Sabljic, E., Norris, D. E., Kraiczy, P., Strle, F. (2005). In Vitro Susceptibility Testing of Borrelia burgdorferi Sensu Lato Isolates Cultured from Patients with Erythema Migrans before and after Antimicrobial Chemotherapy. Antimicrob. Agents Chemother. 49: 1294-1301 [Abstract] [Full Text]  
  • Hunfeld, K.-P., Wichelhaus, T. A., Rodel, R., Acker, G., Brade, V., Kraiczy, P. (2004). Comparison of In Vitro Activities of Ketolides, Macrolides, and an Azalide against the Spirochete Borrelia burgdorferi. Antimicrob. Agents Chemother. 48: 344-347 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»